Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03315533 · ClinicalTrials.gov registry record · Phase 2
Altering The Transition From Acute to Chronic Pain (ATTAC-Pain)
A Phase 2 study of Musculoskeletal Pain, sponsored by Rhode Island Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT03315533 is a Phase 2 study of Musculoskeletal Pain that has completed, run by Rhode Island Hospital. The registered enrollment target is 76 participants, below the 153-participant average among 37 other Musculoskeletal Pain trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03315533, a Phase 2 study of Musculoskeletal Pain, has completed, sponsored by Rhode Island Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The current way that pain is treated after trauma and injury is problematic. Most often pain after trauma is treated with opioids (ex. Percocet® or Vicodin®) or anti-inflammatories (ex. ibuprofen). Both of these medications can cause side effects and opioids have been related to the development of addiction. In addition, there are not any treatments that prevent pain from going on to become persistent (last beyond it is supposed to) or chronic (lasting 3 months or longer). Chronic pain is an enormous problem and there an urgent need to find both alternatives to opioid pain medications and medications that prevent pain from becoming chronic. The ATTAC-Pain (Altering The Transition from Acute to Chronic Pain) study proposes to examine whether duloxetine (a medication that is marketed for depression, anxiety, and specific types of pain conditions), can reduce acute and chronic pain among adults who come to the emergency department (ED)with muscular pain (such as neck pain after a car accident or low back pain). Investigators will enroll 60 patients who come to the ED. Patients will be eligible if they report moderate to severe muscular pain (such as pain in the back, neck, or shoulders). Consenting patients will be randomized to receive duloxetine 30mg, duloxetine 60mg, or placebo (2/3rd chance of being in one of the duloxetine groups). The study team will follow patients for six weeks and collect information on pain outcomes and use of pain medications. Investigators aim to determine if duloxetine can (1) reduce acute pain symptoms following the ED visit, (2) prevent the transition to persistent pain (having pain 6 weeks after the initial ED visit), and (3) decrease opioid use following a motor vehicle collision (MVC). The results of this study will ultimately help determine if duloxetine can be used as a non-opioid pain treatment option that reduces acute pain and prevents the transition to chronic pain. This in turn can improve recovery, reduce opioid use and its c
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Duloxetine 30 milligrams (MG)
- DRUG Duloxetine 60 milligrams (MG)
Study Locations (1)
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2018-01-19 |
| Est. Completion | 2019-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03315533
The ClinicalTrials.gov registry entry for NCT03315533 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 153-participant average among 37 other Musculoskeletal Pain trials with a reported enrollment target (50% lower). The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Musculoskeletal Pain appearing as the primary indexed condition, and to 3 interventions - of which Placebo Oral Tablet is the first listed.
NCT03315533 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT03315533 about?
NCT03315533 is a clinical study titled "Altering The Transition From Acute to Chronic Pain (ATTAC-Pain)". The current way that pain is treated after trauma and injury is problematic. Most often pain after trauma is treated with opioids (ex. Percocet® or Vicodin®) or anti-inflammatories (ex. ibuprofen). Both of these medications can cause side effects and opioids have been related to the development of a...
What is the current status of trial NCT03315533?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2018-01-19. Estimated completion is 2019-04-01.
What conditions does trial NCT03315533 study?
This clinical trial studies the following conditions: Musculoskeletal Pain.
What interventions are being tested in trial NCT03315533?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Duloxetine 30 milligrams (MG) (DRUG), Duloxetine 60 milligrams (MG) (DRUG).
Who is sponsoring clinical trial NCT03315533?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03315533 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Musculoskeletal Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vitamin D to ENhance TraUma REcovery
COMPLETED · Phase 2
-
Group Medical Visits and Chiropractic Care for Older Adults With Chronic Spine Pain
RECRUITING · NA
-
Virtual Reality (VR) Self-Hypnosis Software
RECRUITING · NA
-
The PROACTIVE Study for Black Elders
RECRUITING · NA
-
Overlapping Pain Trajectory Study
RECRUITING
-
Neural Mechanisms of Light Driven Analgesia
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.